Active Filter(s):
Details:
The joint research will focus on using Immgenuity’s IMTV014 and Biostax’s Lodonal™ and JKB-122 both independently and together to determine if the immune modulatory effects of Biostax’s drug therapies combined with Immgenuity’s IMTV014 can achieve remission with HIV patients.
Lead Product(s): IMTVO14,Naltrexone
Therapeutic Area: Infections and Infectious Diseases Product Name: IMTVO14
Highest Development Status: Preclinical Product Type: Vaccine
Partner/Sponsor/Collaborator: Biostax
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2023